Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

AIT Therapeutics announces positive preliminary data for NO-NTM Abscessus Phase 2 clinical trial in NTM patients

Published 11/28/2017, 08:51 AM
© Reuters.  AIT Therapeutics announces positive preliminary data for NO-NTM Abscessus Phase 2 clinical trial in NTM patients
  • AIT Therapeutics (OTCPK:AITB) announces that preliminary results from its NO-NTM Phase 2 study in Nontuberculous Mycobacteria (NTM) targeting patients suffering from Mycobacterium Abscessus Complex (MABSC) indicate that the primary endpoint of safety was met, with no Nitric Oxide-related serious adverse events observed. A potential pivotal trial is expected to begin in the U.S. in the H2 2018 based on the positive results.
  • All patients in the trial were refractory to the standard-of-care for MABSC and had underlying cystic fibrosis. The primary endpoint of safety, as well as the endpoints of mycobacterium abscessus load in sputum and quality-of-life (QoL), assessed at Day 21. The Company anticipates having all data collected by the end of the Q1 2018.
  • MABSC is the most aggressive and difficult to treat form of NTM. There are currently no approved treatments for MABSC.


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.